These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33779268)

  • 21. 6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR).
    Vita GL; Stancanelli C; Gentile L; Barcellona C; Russo M; Di Bella G; Vita G; Mazzeo A
    Neuromuscul Disord; 2019 Mar; 29(3):213-220. PubMed ID: 30718023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atrial cardiomyopathy--a not yet classified cardiomyopathy?
    Dong M; Liu T; Li G
    Int J Cardiol; 2011 Sep; 151(3):394-6. PubMed ID: 21783266
    [No Abstract]   [Full Text] [Related]  

  • 23. Turning Meters Into Years: Walking to Survive Transthyretin Cardiac Amyloidosis.
    Masri A
    J Am Coll Cardiol; 2024 Jul; 84(1):59-60. PubMed ID: 38750977
    [No Abstract]   [Full Text] [Related]  

  • 24. Reduced trans-mitral A-wave velocity predicts the presence of wild-type transthyretin amyloidosis in elderly patients with left ventricular hypertrophy.
    Yamamura S; Izumiya Y; Ishida T; Onoue Y; Kimura Y; Hanatani S; Araki S; Fujisue K; Sueta D; Kanazawa H; Takashio S; Usuku H; Sugamura K; Sakamoto K; Yamamoto E; Yamamuro M; Yasuda H; Kojima S; Kaikita K; Hokimoto S; Ogawa H; Tsujita K
    Heart Vessels; 2017 Jun; 32(6):708-713. PubMed ID: 27882404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transthyretin V122I amyloidosis with clinical and histological evidence of amyloid neuropathy and myopathy.
    Carr AS; Pelayo-Negro AL; Jaunmuktane Z; Scalco RS; Hutt D; Evans MR; Heally E; Brandner S; Holton J; Blake J; Whelan CJ; Wechalekar AD; Gillmore JD; Hawkins PN; Reilly MM
    Neuromuscul Disord; 2015 Jun; 25(6):511-5. PubMed ID: 25819286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted Screening for Transthyretin Amyloid Cardiomyopathy in Patients With Atrial Fibrillation.
    Prasad P; Howell S; Sanghai S; Stecker E; Henrikson CA; Masri A; Nazer B
    Circulation; 2022 Nov; 146(22):1730-1732. PubMed ID: 36441818
    [No Abstract]   [Full Text] [Related]  

  • 27. Inotersen therapy of transthyretin amyloid cardiomyopathy.
    Dasgupta NR; Rissing SM; Smith J; Jung J; Benson MD
    Amyloid; 2020 Mar; 27(1):52-58. PubMed ID: 31713445
    [No Abstract]   [Full Text] [Related]  

  • 28. THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease.
    Wixner J; Mundayat R; Karayal ON; Anan I; Karling P; Suhr OB;
    Orphanet J Rare Dis; 2014 Apr; 9():61. PubMed ID: 24767411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnosis of transthyretin amyloidosis in patients with established cardiomyopathy.
    Martín-Álvarez E; Larrañaga-Moreira JM; Barge-Caballero G; Souto-Caínzos B; Crepo-Leiro MG; Barriales-Villa R
    Rev Esp Cardiol (Engl Ed); 2024 Apr; 77(4):347-349. PubMed ID: 38043734
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.
    Benson MD; Dasgupta NR; Rissing SM; Smith J; Feigenbaum H
    Amyloid; 2017 Dec; 24(4):219-225. PubMed ID: 28906150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Widespread Cardiac and Vasomotor Autonomic Dysfunction in Non-Val30Met Hereditary Transthyretin Amyloidosis.
    Koike H; Nakamura T; Nishi R; Ikeda S; Kawagashira Y; Iijima M; Katsuno M; Sobue G
    Intern Med; 2018 Dec; 57(23):3365-3370. PubMed ID: 29984770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Digoxin Use in Cardiac Amyloidosis.
    Donnelly JP; Sperry BW; Gabrovsek A; Ikram A; Tang WHW; Estep J; Hanna M
    Am J Cardiol; 2020 Oct; 133():134-138. PubMed ID: 32800294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hereditary transthyretin amyloidosis associated with a transthyretin variant Thr59Arg.
    Watanabe T; Obayashi K; Misumi Y; Tasaki M; Shinriki S; Ando T; Akagami T; Ueda M; Yamashita T; Hirotani S; Ando Y
    Amyloid; 2017 Mar; 24(sup1):119. PubMed ID: 28434332
    [No Abstract]   [Full Text] [Related]  

  • 34. Diffusion Tensor Cardiovascular Magnetic Resonance in Cardiac Amyloidosis.
    Khalique Z; Ferreira PF; Scott AD; Nielles-Vallespin S; Martinez-Naharro A; Fontana M; Hawkins P; Firmin DN; Pennell DJ
    Circ Cardiovasc Imaging; 2020 May; 13(5):e009901. PubMed ID: 32408830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure.
    Gagliardi C; Perfetto F; Lorenzini M; Ferlini A; Salvi F; Milandri A; Quarta CC; Taborchi G; Bartolini S; Frusconi S; Martone R; Cinelli MM; Foffi S; Reggiani MLB; Fabbri G; Cataldo P; Cappelli F; Rapezzi C
    Eur J Heart Fail; 2018 Oct; 20(10):1417-1425. PubMed ID: 30070416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.
    Shintani Y; Okada A; Morita Y; Hamatani Y; Amano M; Takahama H; Amaki M; Hasegawa T; Ohta-Ogo K; Kanzaki H; Ishibashi-Ueda H; Yasuda S; Shimazaki C; Yoshinaga T; Yazaki M; Sekijima Y; Izumi C
    ESC Heart Fail; 2019 Feb; 6(1):232-236. PubMed ID: 30478886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality.
    Donnellan E; Wazni OM; Saliba WI; Baranowski B; Hanna M; Martyn M; Patel D; Trulock K; Menon V; Hussein A; Aagaard P; Jaber W; Kanj M
    J Cardiovasc Electrophysiol; 2019 Nov; 30(11):2427-2432. PubMed ID: 31515942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles.
    Knight DS; Zumbo G; Barcella W; Steeden JA; Muthurangu V; Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Kotecha T; Francis R; Rezk T; Quarta CC; Whelan CJ; Lachmann HJ; Wechalekar AD; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    JACC Cardiovasc Imaging; 2019 May; 12(5):823-833. PubMed ID: 29680336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Misconceptions and Facts About Cardiac Amyloidosis.
    Nguyen FD; Rodriguez M; Krittanawong C; Witteles R; Lenihan DJ
    Am J Cardiol; 2021 Dec; 160():99-105. PubMed ID: 34610875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.